Liver Carcinoma — Trials

Liver Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

3,367 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 783
Recruiting: 463
Ph III recruiting: 41
Growth YoY: +1.5%
Industry share: 21%
Top sponsor: Sun Yat-sen University
Termination share: 34.9%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (386)

clinicaltrialsPublishedShowing 1–8 of 8 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06050252	Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery	suspended	Phase 2	27	National Cancer Institute (NCI)NIH	1	Sep 4, 2026	clinicaltrials
NCT06620302	Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma	suspended	Phase 1 / Phase 2	81	Children's Oncology GroupNETWORK	1